Statement: None of the patients in the primary trial had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.
Primary_evidence: Adverse Events 1:   Total: 55/238 (23.11%)   Febrile neutropenia * 5/238 (2.10%)   Neutropenia * 6/238 (2.52%)   Leukopenia * 1/238 (0.42%)   Thrombocytopenia * 0/238 (0.00%)   Anaemia * 1/238 (0.42%)   Pancytopenia * 0/238 (0.00%)   Cardiac failure * 1/238 (0.42%)   Acute coronary syndrome * 0/238 (0.00%)   Atrial fibrillation * 0/238 (0.00%)   Cardiac failure congestive * 0/238 (0.00%) Adverse Events 2:   Total: 89/245 (36.33%)   Febrile neutropenia * 12/245 (4.90%)   Neutropenia * 10/245 (4.08%)   Leukopenia * 2/245 (0.82%)   Thrombocytopenia * 5/245 (2.04%)   Anaemia * 1/245 (0.41%)   Pancytopenia * 1/245 (0.41%)   Cardiac failure * 2/245 (0.82%)   Acute coronary syndrome * 1/245 (0.41%)   Atrial fibrillation * 1/245 (0.41%)   Cardiac failure congestive * 2/245 (0.82%)